
Sign up to save your podcasts
Or
In America and Europe, a growing number of clinics are offering ketamine to treat depression. The anaesthetic—also used illegally as a party drug—can provide rapid relief from the condition where traditional treatments, such as antidepressant drugs, have failed. We investigate how the therapy works, and ask what role it will play in the future of mental-health care. And, as ketamine treatments spread, is enough known about the drug’s long-term safety? Alok Jha hosts with Natasha Loder, The Economist’s health policy editor.
For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience.
Hosted on Acast. See acast.com/privacy for more information.
4.8
570570 ratings
In America and Europe, a growing number of clinics are offering ketamine to treat depression. The anaesthetic—also used illegally as a party drug—can provide rapid relief from the condition where traditional treatments, such as antidepressant drugs, have failed. We investigate how the therapy works, and ask what role it will play in the future of mental-health care. And, as ketamine treatments spread, is enough known about the drug’s long-term safety? Alok Jha hosts with Natasha Loder, The Economist’s health policy editor.
For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience.
Hosted on Acast. See acast.com/privacy for more information.
4,208 Listeners
527 Listeners
917 Listeners
363 Listeners
96 Listeners
224 Listeners
108 Listeners
2,530 Listeners
45 Listeners
1,069 Listeners
1,415 Listeners
138 Listeners
116 Listeners
101 Listeners
36 Listeners
890 Listeners
344 Listeners
496 Listeners
78 Listeners
68 Listeners
123 Listeners
100 Listeners
252 Listeners